| Literature DB >> 25407810 |
João Perdigão, Hugo Silva, Diana Machado, Rita Macedo, Fernando Maltez, Carla Silva, Luisa Jordao, Isabel Couto, Kim Mallard, Francesc Coll, Grant A Hill-Cawthorne, Ruth McNerney, Arnab Pain, Taane G Clark, Miguel Viveiros, Isabel Portugal1.
Abstract
BACKGROUND: Multidrug- (MDR) and extensively drug resistant (XDR) tuberculosis (TB) presents a challenge to disease control and elimination goals. In Lisbon, Portugal, specific and successful XDR-TB strains have been found in circulation for almost two decades.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25407810 PMCID: PMC4289236 DOI: 10.1186/1471-2164-15-991
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Isolate characteristics: DST and data derived from WGS including mapping indicators
| Isolate | DST a | SCG | PGG | Spoligotype b | SNPs | INDELs c | Mapping Indicators d | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First-Line | Second-Line | SIT | Clade | Non-synonymous mutations (N s ) | Synonymous mutations (S) | Total in Coding Regions (T c ) | Total in Non-Coding Regions | Total | N s /S Ratio | T v /T s Ratio | T c /Total | Total | Size Range | Mean Read Depth | Coverage (%) | |||
| ARS10348 | IRS | ETH | 5 | 2 | 20 | LAM1 | 410 | 296 | 706 | 243 | 949 | 1.3851 | 0.5865 | 0.7439 | 96 | 1-24 | 135.18 | 98.86 |
| ARS11131 | IRSP | CAP AMK OFX MOX ETH | 5 | 2 | 1106 | LAM4 | 381 | 286 | 667 | 237 | 904 | 1.3322 | 0.6308 | 0.7378 | 95 | 1-24 | 101.56 | 98.89 |
| ARS11285 | IRS | AMK OFX MOX | 4 | 2 | 119 | X1 | 429 | 302 | 731 | 283 | 1014 | 1.4205 | 0.6031 | 0.7209 | 114 | 1-37 | 159.38 | 99.83 |
| ARS11463 | I | nd | 5 | 2 | 64 | LAM6 | 382 | 255 | 637 | 241 | 878 | 1.4980 | 0.5575 | 0.7255 | 76 | 1-24 | 52.42 | 99.47 |
| ARS11661 | IS | nd | 5 | 2 | 1106 | LAM4 | 378 | 284 | 662 | 234 | 896 | 1.3310 | 0.6443 | 0.7388 | 96 | 1-24 | 110.16 | 98.84 |
| ARS12740 | IRSP | ETH | 5 | 2 | 1106 | LAM4 | 392 | 287 | 679 | 239 | 918 | 1.3659 | 0.6456 | 0.7397 | 95 | 1-24 | 97.66 | 98.81 |
| ARS1717 | IRP | OFX ETH | 6a | 3 | 2258 | Unknown | 263 | 158 | 421 | 160 | 581 | 1.6646 | 0.5651 | 0.7246 | 67 | 1-27 | 68.89 | 99.76 |
| ARS1760 | I | nd | 5 | 2 | 64 | LAM6 | 379 | 262 | 641 | 242 | 883 | 1.4466 | 0.5725 | 0.7259 | 83 | 1-53 | 69.23 | 99.40 |
| ARS1900 | IRSEP | CAP KAN OFX ETH | 5 | 2 | 20 | LAM1 | 414 | 301 | 715 | 250 | 965 | 1.3754 | 0.6009 | 0.7409 | 101 | 1-24 | 148.85 | 98.75 |
| ARS1930 | IRSP | na | 5 | 2 | 42 | LAM9 | 389 | 268 | 657 | 228 | 885 | 1.4515 | 0.6158 | 0.7424 | 90 | 1-52 | 90.43 | 98.81 |
| ARS2061 | IRP | CAP AMK KAN OFX ETH CS PAS | 5 | 2 | 1106 | LAM4 | 379 | 283 | 662 | 239 | 901 | 1.3392 | 0.6346 | 0.7347 | 89 | 1-24 | 80.51 | 98.83 |
| ARS2202 | IRSP | OFX ETH CS | 5 | 2 | 20 | LAM1 | 404 | 284 | 688 | 243 | 931 | 1.4225 | 0.5889 | 0.7390 | 91 | 1-24 | 79.46 | 98.99 |
| ARS2573 | I | nd | 5 | 2 | 20 | LAM1 | 400 | 277 | 677 | 231 | 908 | 1.4440 | 0.6250 | 0.7456 | 97 | 1-49 | 82.71 | 99.03 |
| ARS3649 | IRSEP | KAN OFX ETH | 5 | 2 | 20 | LAM1 | 399 | 282 | 681 | 242 | 923 | 1.4149 | 0.5814 | 0.7378 | 91 | 1-24 | 72.67 | 98.92 |
| ARS3806 | I | nd | 5 | 2 | 2535 | Unknown | 386 | 283 | 669 | 233 | 902 | 1.3640 | 0.6277 | 0.7417 | 85 | 1-24 | 195.56 | 98.84 |
| ARS4857 | IRP | na | 5 | 2 | 1106 | LAM4 | 381 | 279 | 660 | 234 | 894 | 1.3656 | 0.6418 | 0.7383 | 92 | 1-24 | 91.12 | 98.86 |
| ARS5858 | IREP | OFX | 5 | 2 | 20 | LAM1 | 395 | 284 | 679 | 243 | 922 | 1.3908 | 0.6401 | 0.7364 | 102 | 1-24 | 142.10 | 98.98 |
| ARS6483 | IRSEP | OFX ETH | 5 | 2 | 20 | LAM1 | 406 | 303 | 709 | 246 | 955 | 1.3399 | 0.5839 | 0.7424 | 98 | 1-24 | 92.22 | 98.79 |
| ARS6539 | IS | nd | 5 | 2 | 20 | LAM1 | 407 | 303 | 710 | 249 | 959 | 1.3432 | 0.5933 | 0.7404 | 63 | 1-24 | 273.98 | 98.87 |
| ARS6559 | I | nd | 5 | 2 | 81 | LAM9 | 394 | 292 | 686 | 233 | 919 | 1.3493 | 0.5953 | 0.7465 | 86 | 1-24 | 63.55 | 98.76 |
| ARS7496 | IS | nd | 2 | 1 | 1 | Beijing | 589 | 410 | 999 | 405 | 1404 | 1.4366 | 0.6404 | 0.7115 | 175 | 1-39 | 109.62 | 99.30 |
| ARS7571 | I | nd | 5 | 2 | 211 | LAM3 | 388 | 265 | 653 | 244 | 897 | 1.4642 | 0.5749 | 0.7280 | 93 | 1-24 | 123.02 | 99.48 |
| ARS7860 | IS | nd | 5 | 2 | 811 | LAM4 | 378 | 279 | 657 | 232 | 889 | 1.3548 | 0.6318 | 0.7390 | 86 | 1-24 | 72.59 | 98.60 |
| ARS7884 | IRSEP | OFX ETH | 5 | 2 | 20 | LAM1 | 409 | 300 | 709 | 244 | 953 | 1.3633 | 0.5874 | 0.7440 | 100 | 1-24 | 177.31 | 98.81 |
| ARS8437 | IRSP | CAP ETH | 5 | 2 | 20 | LAM1 | 405 | 296 | 701 | 247 | 948 | 1.3682 | 0.6005 | 0.7395 | 92 | 1-24 | 179.07 | 98.78 |
| ARS8600 | I | nd | 5 | 2 | 20 | LAM1 | 407 | 291 | 698 | 238 | 936 | 1.3986 | 0.6262 | 0.7457 | 74 | 1-49 | 254.44 | 98.97 |
| ARS9427 | I | nd | 3a | 1 | 26 | CAS1-Delhi | 632 | 411 | 1043 | 422 | 1465 | 1.5377 | 0.5773 | 0.7119 | 152 | 1-36 | 44.07 | 99.82 |
| FF181_97 | IRS | na | 5 | 2 | 20 | LAM1 | 417 | 300 | 717 | 249 | 966 | 1.3900 | 0.6185 | 0.7422 | 24 | 1-9 | 772.29 | 98.99 |
| FF291_98 | IRS | na | 5 | 2 | 20 | LAM1 | 416 | 294 | 710 | 250 | 960 | 1.4150 | 0.6063 | 0.7396 | 31 | 1-18 | 658.49 | 98.97 |
| FF359_98 | IRS | na | 5 | 2 | 20 | LAM1 | 419 | 293 | 712 | 254 | 966 | 1.4300 | 0.5946 | 0.7371 | 31 | 1-18 | 836.93 | 99.01 |
| FF674_96 | Susceptible | na | 4 | 2 | 91 | X3 | 428 | 323 | 751 | 276 | 1027 | 1.3251 | 0.6047 | 0.7313 | 34 | 1-33 | 961.69 | 99.76 |
| HCC1095_10 | IRE | nd | 3b | 2 | 53 | T1 | 429 | 314 | 743 | 292 | 1035 | 1.3662 | 0.5577 | 0.7179 | 119 | 1-24 | 185.45 | 99.61 |
| HCC1276_11 | IRSEP | CAP AMK OFX MOX ETH | 5 | 2 | 1106 | LAM4 | 392 | 281 | 673 | 243 | 916 | 1.3950 | 0.6350 | 0.7347 | 96 | 1-24 | 159.36 | 98.81 |
| HCC1470_11 | IRSEP | CAP AMK KAN OFX MOX ETH CS PAS | 5 | 2 | 20 | LAM1 | 412 | 295 | 707 | 251 | 958 | 1.3966 | 0.5830 | 0.7380 | 99 | 1-24 | 96.90 | 98.76 |
| HCC759_09 | IR | ETH | 2 | 1 | 1 | Beijing | 623 | 414 | 1037 | 418 | 1455 | 1.5048 | 0.6102 | 0.7127 | 160 | 1-28 | 70.73 | 99.39 |
| HCC916_10 | IRSEP | CAP AMK KAN OFX ETH | 5 | 2 | 1106 | LAM4 | 373 | 281 | 654 | 238 | 892 | 1.3274 | 0.6044 | 0.7332 | 103 | 1-24 | 145.85 | 98.82 |
| HPV105_09 | S | nd | 5 | 2 | 1752 | LAM1 | 400 | 281 | 681 | 244 | 925 | 1.4235 | 0.6214 | 0.7362 | 37 | 1-22 | 591.50 | 98.93 |
| HPV113_08 | IRSEP | ETH | 6a | 3 | 54 | MANU2 | 222 | 126 | 348 | 140 | 488 | 1.7619 | 0.5945 | 0.7131 | 62 | 1-24 | 167.28 | 99.94 |
| HPV115_08 | IRSEP | CAP AMK KAN OFX ETH | 5 | 2 | 1106 | LAM4 | 312 | 225 | 537 | 196 | 733 | 1.3867 | 0.7318 | 0.7326 | 76 | 1-21 | 179.43 | 98.82 |
| HPV157_06 | IS | nd | 5 | 2 | 17 | LAM2 | 397 | 287 | 684 | 248 | 932 | 1.3833 | 0.5760 | 0.7339 | 90 | 1-24 | 96.25 | 98.87 |
| HPV50_09 | Susceptible | nd | 5 | 2 | 20 | LAM1 | 397 | 291 | 688 | 238 | 926 | 1.3643 | 0.6554 | 0.7430 | 69 | 1-24 | 281.12 | 98.94 |
| HPV51_09 | Susceptible | nd | 3c | 2 | 137 | X2 | 420 | 309 | 729 | 276 | 1005 | 1.3592 | 0.5677 | 0.7254 | 29 | 1-18 | 632.88 | 99.60 |
| HPV65_08 | Susceptible | nd | 6a | 3 | Unknown | Unknown | 247 | 160 | 407 | 162 | 569 | 1.5438 | 0.5837 | 0.7153 | 15 | 1-18 | 1149.11 | 99.57 |
| HPV70_09 | Susceptible | nd | 5 | 2 | 1803 | LAM1 | 380 | 277 | 657 | 224 | 881 | 1.3718 | 0.6343 | 0.7457 | 26 | 1-45 | 1410.21 | 99.65 |
| HVNG1 | IRSEP | CAP AMK KAN | 5 | 2 | 20 | LAM1 | 308 | 225 | 533 | 201 | 734 | 1.3689 | 0.7082 | 0.7262 | 76 | 1-24 | 154.30 | 98.78 |
| IHMT134_09 | IRSP | RFB ETH | 5 | 2 | 20 | LAM1 | 332 | 228 | 560 | 203 | 763 | 1.4561 | 0.6935 | 0.7339 | 83 | 1-24 | 171.49 | 98.77 |
| IHMT149_09 | IRSEP | RFB CAP AMK OFX MOX ETH | 5 | 2 | 1106 | LAM4 | 313 | 226 | 539 | 193 | 732 | 1.3850 | 0.6849 | 0.7363 | 75 | 1-21 | 168.54 | 98.81 |
| IHMT194_11 | IRSEP | RFB CAP AMK ETH | 5 | 2 | 1106 | LAM4 | 382 | 274 | 656 | 236 | 892 | 1.3942 | 0.6318 | 0.7354 | 83 | 1-24 | 47.61 | 98.96 |
| IHMT288_95 | IRSP | RFB ETH | 5 | 2 | 20 | LAM1 | 415 | 304 | 719 | 247 | 966 | 1.3651 | 0.6230 | 0.7443 | 98 | 1-24 | 197.48 | 98.84 |
| IHMT295_08 | IRSEP | RFB ETH | 2 | 1 | 1 | Beijing | 528 | 337 | 865 | 358 | 1223 | 1.5668 | 0.7284 | 0.7073 | 127 | 1-59 | 181.48 | 99.18 |
| IHMT308_08 | IRP | RFB ETH | 5 | 2 | 1106 | LAM4 | 334 | 228 | 562 | 201 | 763 | 1.4649 | 0.7524 | 0.7366 | 76 | 1-21 | 205.47 | 98.79 |
| IHMT359_03 | R | nd | 5 | 2 | Orphan | LAM1 | 406 | 289 | 695 | 247 | 942 | 1.4048 | 0.6276 | 0.7378 | 31 | 1-22 | 727.91 | 98.93 |
| IHMT361_08 | IREP | CAP ETH | 5 | 2 | 1106 | LAM4 | 305 | 232 | 537 | 193 | 730 | 1.3147 | 0.6278 | 0.7356 | 70 | 1-24 | 191.20 | 98.80 |
| IHMT69_11 | IRSEP | RFB CAP AMK ETH | 2 | 1 | 1 | Beijing | 609 | 420 | 1029 | 415 | 1444 | 1.4500 | 0.6307 | 0.7126 | 169 | 1-39 | 202.92 | 99.36 |
| IHMT80_11 | IRSEP | RFB CAP AMK ETH | 5 | 2 | 1106 | LAM4 | 380 | 277 | 657 | 236 | 893 | 1.3718 | 0.6318 | 0.7357 | 87 | 1-24 | 63.98 | 98.95 |
| IHMT82_09 | IRS | RFB CAP ETH | 5 | 2 | 20 | LAM1 | 313 | 221 | 534 | 190 | 724 | 1.4163 | 0.6808 | 0.7376 | 81 | 1-24 | 121.47 | 98.69 |
aFirst-Line: I - Isoniazid, R - Rifampicin, S - Streptomycin, E - Ethambutol, P - Pyrazinamide; Second-Line: ETH - Ethionamide, KAN - Kanamycin, AMK - Amikacin, OFX - Ofloxacin, MOX - Moxifloxacin, RFB - Rifabutin, PAS - Para-amino salicylic acid, CS - Cycloserine.
bSpoligotype inferred from SpolPred software (Coll et al., [89]).
cSmall INDELs called by SAMtools from mapping to M. tuberculosis H37Rv.
dRelative to M. tuberculosis H37Rv.
na, Not available.
nd, Not done.
Figure 1MIRU-VNTR genotypic analysis of the 56 isolates. MIRU-VNTR dendrogram of the 56 M. tuberculosis clinical isolates subjected to WGS. First-line drug susceptibility testing: I, INH; R, RIF; S, STP; E, EMB; P, PZA. Second-line drug susceptibility testing: KAN, kanamycin; AMK, amikacin; CAP, capreomycin; OFX, ofloxacin; MOX, moxifloxacin; ETH, ethionamide; PAS, para-amino salicylic acid; CS, cycloserine; na, not available, nd, not determined.
Figure 2genome-wide SNP-based phylogeny. Phylogenetic tree (A) and cladogram (B) of the initial 56 clinical isolates plus 20 M. tuberculosis public genomes. PGGs are highlighted in green (PGG1), blue (PGG2) and red (PGG3). A - Isolate-depicting symbols are representative of the different SCGs found in the tree: SCG 1 (yellow square), SCG 2 (black squares), SCG 3a (green triangle), SCG 3b (red triangle), SCG 3c (blue triangle), SCG 4 (black triangles), SCG 5 (circles), SCG 6a (green diamonds), SCG 6b (red diamond). Lisboa3 and Q1 strains are represented by red and blue circles (within SCG 5), respectively.
Figure 3Microevolution from susceptible TB towards MDR- and XDR-TB. Lisboa3 (A) and Q1 (B) subtree cladograms highlighting the microevolutionary path towards MDR and XDR within these two phylogenetic clades. Mutations acquired in genes associated with first and second-line drug resistance are shown in branch or associated node.
Candidate RIF resistance compensatory mutations found in RpoA, RpoB, and RpoC among RIF-resistant isolates with other RIF resistant associated mutations in RpoB
| Protein | Mutation | SCG | No. of Isolates | SIFT Score |
|---|---|---|---|---|
| RpoA | E184D | 2 | 1 | 0.09 |
| RpoB | P45A | 5 | 1 | 0.01 |
| RpoB | T328N | 2 | 1 | 0.03 |
| RpoB | L452P | 5 | 2 | 0.00 |
| RpoB | V496A | 6a | 1 | 0.10 |
| RpoB | D634G | 5 | 1 | 0.49 |
| RpoB | L731P | 2, 5 | 13 | 0.00 |
| RpoB | E812G | 2 | 1 | 0.08 |
| RpoB | I1106T | 5 | 2 | 0.00 |
| RpoC | G442C | 5 | 1 | 0.00 |
| RpoC | W484G | 2 | 1 | 0.00 |
| RpoC | D747G | 4 | 1 | 0.35 |
| RpoC | K1152Q | 5 | 4 | 0.00 |
| RpoC | S1287L | 6a | 1 | 0.23 |
Figure 4Mapping of IS insertion sites. Genomic distribution of total mapped IS6110, intra and intergenic, and insertion sites found among Lisboa3 and Q1 isolates. Lisboa3 core and Q1 lanes depicts all insertion sites that are common to all Lisboa3 and Q1 clade isolates, respectively. Lisboa3 node B1 comprises a XDR-TB lineage shown here with an extra IS6110 copy. Lisboa3-A (node D1) are shown here to bear three additional IS6110 copies when compared with the Lisboa3 core.